Poland· PL-100539336
Xolremdi
A other immunostimulants product containing mavorixafor, registered in Poland by X4 Pharmaceuticals (Austria) GmbH. The same ATC class is registered in 8 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Mavorixafor is registered in 8 of 19 countries.
Countries holding a registration under ATC L03AX (other immunostimulants), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Mavorixafor · ATC L03AX
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Mavorixafor
- Manufacturer
- X4 Pharmaceuticals (Austria) GmbH
- Country
- Poland (PL)
- ATC code
- L03AX
- ATC class
- Other immunostimulants
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mavorixafor in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXOLREMDINorgine B.V., Amsterdam
- FinlandXolremdiNorgine B.V.
- BelgiumXolremdi 100 mgNorgine
- IcelandXolremdiNorgine B.V.
- NetherlandsXolremdi 100 mg harde capsuleNorgine B.V.
- SwedenXolremdi 100 mg Kapsel, hårdNorgine BV
- IrelandXolremdi 100mg hard capsuleNorgine B.V.
- United StatesXOLREMDIX4 Pharmaceuticals, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Xolremdi
- Liechtenstein · Xolremdi
- Norway · Xolremdi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/057201e6-8d1f-4a6f-b5ac-de0ef207101d GET /v1/drugs/057201e6-8d1f-4a6f-b5ac-de0ef207101d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "100 mg",
"packaging": "Rpz ¦ EU/1/26/2017/001 ¦ 167311\n60 kaps.\nRpz ¦ EU/1/26/2017/002 ¦ 167312\n90 kaps.\nRpz ¦ EU/1/26/2017/003 ¦ 167313\n120 kaps.",
"substance": "Mavorixafor 100 mg",
"common_name": "Mavorixafor",
"pl_product_id": "100539336",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about mavorixafor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.